Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have been assigned a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $48.10.

A number of research analysts have recently issued reports on KYMR shares. Credit Suisse Group boosted their target price on Kymera Therapeutics from $36.00 to $37.00 and gave the company a “neutral” rating in a report on Friday, August 4th. Stifel Nicolaus lifted their price target on Kymera Therapeutics from $48.00 to $52.00 and gave the company a “buy” rating in a research note on Monday, August 7th. Morgan Stanley decreased their price target on Kymera Therapeutics from $39.00 to $37.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 29th. HC Wainwright restated a “buy” rating and issued a $85.00 price target on shares of Kymera Therapeutics in a research note on Friday, August 4th. Finally, Truist Financial assumed coverage on Kymera Therapeutics in a research note on Friday, June 30th. They issued a “buy” rating and a $50.00 price target on the stock.

Institutional Trading of Kymera Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its holdings in shares of Kymera Therapeutics by 34.1% in the second quarter. Price T Rowe Associates Inc. MD now owns 5,224,686 shares of the company’s stock worth $102,874,000 after acquiring an additional 1,329,481 shares during the last quarter. BVF Inc. IL raised its holdings in shares of Kymera Therapeutics by 1.0% in the first quarter. BVF Inc. IL now owns 4,739,004 shares of the company’s stock worth $140,417,000 after acquiring an additional 46,400 shares during the last quarter. Avoro Capital Advisors LLC raised its holdings in shares of Kymera Therapeutics by 77.5% in the fourth quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock worth $96,096,000 after acquiring an additional 1,680,770 shares during the last quarter. State Street Corp raised its holdings in shares of Kymera Therapeutics by 67.8% in the second quarter. State Street Corp now owns 3,514,438 shares of the company’s stock worth $69,199,000 after acquiring an additional 1,419,877 shares during the last quarter. Finally, BlackRock Inc. raised its holdings in shares of Kymera Therapeutics by 0.6% in the first quarter. BlackRock Inc. now owns 3,419,084 shares of the company’s stock worth $144,698,000 after acquiring an additional 21,544 shares during the last quarter.

Kymera Therapeutics Trading Down 0.2 %

NASDAQ:KYMR opened at $18.94 on Monday. The firm has a market cap of $1.05 billion, a P/E ratio of -6.86 and a beta of 1.51. The stock’s 50 day simple moving average is $21.01 and its 200-day simple moving average is $26.38. Kymera Therapeutics has a 12-month low of $18.53 and a 12-month high of $39.85.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, August 3rd. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.03. The business had revenue of $16.51 million for the quarter, compared to analyst estimates of $13.93 million. Kymera Therapeutics had a negative return on equity of 33.17% and a negative net margin of 305.01%. The company’s revenue for the quarter was up 43.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.78) earnings per share. Research analysts forecast that Kymera Therapeutics will post -2.55 EPS for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.